CAMBRIDGE, UK--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter ...

OverT Bio, an NYC-based cell therapy company, today announced that it has been awarded a $120,000 G-Rex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation ...

Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a validated cell therapy approach, rather than ...

Editor's note: This story was updated at 210p ET with details on price, availability, and "black box" warning. The U.S. FDA Friday approved bluebird bio's (NASDAQ:BLUE) Lyfgenia (lovo-cel), a gene ...

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%. The overhaul, ...

Breakthrough Therapy Designation is based on the encouraging survival data from the Phase 1 BrainChild-03 trial in children and young adults with diffuse intrinsic pontine glioma (DIPG) BrainChild Bio ...

Bluebird Bio, a company that steered three gene therapies to FDA approval but struggled to commercialize them, has found the cash it needs to put those therapies on stronger financial footing by ...

Belite Bio, Inc. announced that the FDA has granted Breakthrough Therapy Designation for its drug Tinlarebant, intended for the treatment of Stargardt disease (STGD1), based on promising interim ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a competitive ...